MedEDirect is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation: MedEDirect designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants must participate in the session and complete an activity evaluation before November 24, 2015.
MedEDirect is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Activity Number 0498-0000-14-009-H01-P and will award 2.0 contact hours (0.2 CEUs). Successful completion of the activity includes participating in the session, completing an activity evaluation before November 24, 2015, and passing a post-test with a minimum score of 70%.
Scientific Integrity and Disclosure of Financial Interests
This activity is supported by an unrestricted educational grant from Theravance Biopharma Antibiotics, Inc.
Andrew F. Shorr, MD, MPH receives lecture fees and grant support from and serves as a consultant/advisor to Astellas Pharma, AstraZeneca, Bayer, Cubist Pharmaceuticals, Endoclear, Forest Laboratories, Nabriva Therapeutics, Roche, Tetraphase Pharmaceuticals, and Pfizer.
Keith A. Rodvold, PharmD receives lecture fees from Cubist Pharmaceuticals and Forest Laboratories, and grant support from Forest and Theravance Biopharma. He serves as a consultant/advisor to Cempra Pharmaceuticals, Cubist, Durata Therapeutics, Forest, The Medicines Company, Roche–Genentech, Sanofi, Shionogi, Tetraphase Pharmaceuticals, and Theravance.
G. Ralph Corey, MD serves as a consultant/advisor to Achaogen, Cempra Pharmaceuticals, Cubist Pharmaceuticals, Forest/Cerexa, GlaxoSmithKline, The Medicines Company, Merck, Rib-X Pharmaceuticals, Theravance Biopharma, and Trius Therapeutics. He has served as a primary investigator or otherwise participated in clinical trials for Dr. Reddy’s Laboratories, Forest/Cerexa, GlaxoSmithKline, The Medicines Company, Merck, Pfizer, and Theravance.
Thomas Zimmerman, PhD (Reviewer, MedEDirect) has nothing to disclose.
Danielle Amodio (MedEDirect) has nothing to disclose.
Andrew F. Shorr, MD, MPH
Associate Chief, Pulmonary and Critical Care
Washington Hospital Center
Associate Professor of Medicine
Georgetown University Hospital
Click here to view Andrew F. Shorr, MD’s Bio
Keith A. Rodvold, PharmD, FCCP, FIDSA
Professor of Pharmacy Practice and Pharmacy in Medicine
Colleges of Pharmacy and Medicine
Co-Director, Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago
Click here to view Keith A. Rodvold, PharmD’s Bio
G. Ralph Corey, MD Infectious Diseases
Professor of Medicine
Duke University Medical Center
Click here to view G. Ralph Corey, MD’s Bio
To claim credit for participation in this activity, please click the "Proceed to Test" button below.
Physicians: Complete the post test and program evaluation. Once submitted, you will be able to download your certificate.
Pharmacists: You must pass the test with a score of 70% or higher. Upon passing the post-test you will be led to the program evaluation. Once you have completed the program evaluation, proof of participation will be forwarded to ACPE/NABP and you will be able to download a copy of your certificate for your records.
ON DEMAND: Evolving Aspects of Gram-positive Infections: Changing Bugs, Drugs, & Endpoints